Fig. 5

Effect of F11R/JAM-A-derived peptide (P4D) on cell proliferation evaluated by BrdU incorporation assay. The cells were untreated (Ctrl), treated with the control scrambled peptide (Scr) or with the F11R/JAM-A antagonistic peptide (P4D) at a concentration of 500 μM. The data were tested for normality by Shapiro–Wilk W test: EA.hy926 – passed (P-values for Ctrl: 0.6137, for Scr: 0.4433, for P4D: 0.2206); HMEC-1 – passed (P-values for Ctrl: 0.9044, for Scr: 0.3065, for P4D: 0.2034); MDA-MB-231 – failed (P-values for Ctrl: 0.0009, for Scr: 0.0013, for P4D: 0.1616). The data falling into the Gaussian distribution were statistically analyzed by ANOVA (P = 0.0419 for EA.hy926: the differences between the tested groups are statistically significant; P = 0.0956 for HMEC-1: no statistically significant differences) followed, where applicable, by Tukey's multiple comparisons test. Otherwise, the results were analyzed by Kruskal–Wallis test (P < 0.0001 for MDA-MB-231: significant differences between the experimental groups) followed by Dunn's multiple comparisons test. Tukey’s multiple comparisons test for EA.hy926: Ctrl vs. Scr P = 0.1542; Ctrl vs. P4D P = 0.0121; Scr vs. P4D P = 0.5348. Dunn’s multiple comparisons test for MDA-MB-231: Ctrl vs. Scr P = 0.8186; Ctrl vs. P4D P < 0.0001; Scr vs. P4D P = 0.0004